Diagnostic Efficacy of Serum PIVKA-Ⅱ Detection in Primary Hepatocellular Carcinoma

Li-xian YUAN; Hong-tao ZHANG; Rui LI; Kun-rui CHEN; Kun-qian CHEN; An-shu XU

doi:10.12259/j.issn.2095-610X.S20201223

Volume 41 Issue 12

Dec. 2019

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2020 > 41(12): 80-84

Li-xian YUAN, Hong-tao ZHANG, Rui LI, Kun-rui CHEN, Kun-qian CHEN, An-shu XU. Diagnostic Efficacy of Serum PIVKA-Ⅱ Detection in Primary Hepatocellular Carcinoma[J]. Journal of Kunming Medical University, 2020, 41(12): 80-84. doi: 10.12259/j.issn.2095-610X.S20201223

Citation:

Li-xian YUAN, Hong-tao ZHANG, Rui LI, Kun-rui CHEN, Kun-qian CHEN, An-shu XU. Diagnostic Efficacy of Serum PIVKA-Ⅱ Detection in Primary Hepatocellular Carcinoma[J]. Journal of Kunming Medical University, 2020, 41(12): 80-84. doi: 10.12259/j.issn.2095-610X.S20201223

Citation:

PDF( 674 KB)

Diagnostic Efficacy of Serum PIVKA-Ⅱ Detection in Primary Hepatocellular Carcinoma

doi: 10.12259/j.issn.2095-610X.S20201223

1.
Dept. of Nuclear Medicine
2.
Dept. of the Medical Affairs
3.
Dept. of Infectious Diseases
4.
Dept. of Cardiovascular Surgery
5.
Dept. of General Surgery, Qujing Affiliated Hospital of Kunming Medical University, Qujing Yunnan 655000, China

Received Date: 2020-04-16
Publish Date: 2020-12-25

Abstract

Abstract

Objective To explore the diagnostic efficacy of serum Protein induced by vitamin K absence or antagonist-Ⅱ（PIVKA-Ⅱ）in Primary hepatocellular carcinoma. Methods 150 patients who diagnosed and treated in Qujing Affiliated Hospital of Kunming Medical University were divided into chronic hepatitis B group（HBV, n = 50）, chronic hepatitis C group（HCV, n = 50）and Hepatocellular carcinoma group（HCC, n = 50）, and 50 healthy people were selected as normal control group. Serum PIVKA-Ⅱ concentration were detected by Fujirebio-Lumipulse G1200 system and alpha fetoprotein（AFP）concentration were detected by Roche Cobas e601 immunoassay system. Results The serum PIVKA-Ⅱ and AFP concentrations in HCC group were significantly higher than those in chronic liver disease groups and normal control group（P < 0.05）. The sensitivity and specificity of PIVKA-Ⅱ in the diagnosis of HCC were 94.0% and 95.3%, compared with AFP’ s 76.0% and 90.0% for specificity, respectively. Subjects operating characteristic curve（ROC）showed that the areas under curve of PIVKA-Ⅱ and AFP were 0.963 and 0.848, respectively. Conclusions The diagnostic efficacy of Serum PIVKA-Ⅱ is better than AFP in diagnosing Primary Hepatocellular Carcinoma and can be used in clinical practice.
- Hepatocellular carcinoma,
- Chronic hepatitis B,
- Chronic hepatitis C,
- Protein induced by vitamin K absence or antagonist-Ⅱ,
- Alpha-fetoprotein

FullText(HTML)

References(25)

References

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
[2]	中华预防医学会肿瘤预防与控制专业委员会感染相关肿瘤防控学组, 中华预防医学会慢病预防与控制分会, 中华预防医学会健康传播分会. 中国肝癌一级预防专家共识(2018)[J]. 中华预防医学杂志, 2019, 53(1): 36-44.
[3]	Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2012,379(9822):1245-1255.
[4]	Tsuchiya N, Sawada Y, Endo I, et al. Biomarkers for the early diagnosis of hepatocellularcarcinoma[J]. World J Gastroenterol, 2015,21(37):10573-10583.
[5]	Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice guidelines proposed by the Japan society of hepatology(JSH) 2010 updated version[J]. Digestive Diseases, 2011, 29(3): 339-364. doi: 10.1159/000327577
[6]	中华人民共和国卫生部(卫办医政发〔2011〕121号). 原发性肝癌诊疗规范(2011年版)[J]. 临床肿瘤学杂志, 2011, 16(10): 929-946. doi: 10.3969/j.issn.1009-0460.2011.10.017
[7]	王贵强, 王福生, 成军, 等. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. doi: 10.3969/j.issn.1001-5256.2015.12.002
[8]	中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 中华肝脏病杂志, 2019,27(12): 962-979.
[9]	安澜, 曾红梅, 郑荣寿, 等. 2015年中国肝癌流行情况分析[J]. 中华肿瘤杂志, 2019, 41(10): 721-727.
[10]	Sauzay C, Petit A, Bourgeois AM, et al. Alpha-foetoprotein(AFP): A multi-purpose marker in hepatocellular carcinoma[J]. Clin Chim Acta, 2016, 463: 39-44. doi: 10.1016/j.cca.2016.10.006
[11]	Zhang YS, Chu JH, Cui SX, et al. Des-γ-carboxy prothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma[J]. Cell Physiol Biochem, 2014, 34(3): 903-915. doi: 10.1159/000366308
[12]	Inagaki Y, Tang W, Makuuchi M, et al. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin[J]. Liver Int, 2011, 31(1): 22-35. doi: 10.1111/j.1478-3231.2010.02348.x
[13]	Liebman HA, Furie BC, Tong MJ, et al. Des-gamma-carboxy (Abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma[J]. N Engl J Med, 1984, 310(22): 1427-1431. doi: 10.1056/NEJM198405313102204
[14]	Song P, Gao J, Inagaki Y, et al. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china[J]. Liver Cancer, 2013, 2(1): 31-39. doi: 10.1159/000346220
[15]	Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxyprothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma[J]. Gastroenterology, 2010, 138(2): 493-502. doi: 10.1053/j.gastro.2009.10.031
[16]	Park SJ, Jang JY, Jeong SW, et al. Usefulness of AFP, AFP-L3, and PIVKA-Ⅱ, and their combinations in diagnosing hepatocellular carcinoma[J]. Medicine(Baltimore), 2017, 96(11): e5811.
[17]	Poté N, Cauchy F, Albuquerque M, et al. Performance of PIVKA-Ⅱ for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion[J]. J Hepatol, 2015, 62(4): 848-854. doi: 10.1016/j.jhep.2014.11.005
[18]	朱宇, 王海, 王宏洁, 等. 血清PIVKA-Ⅱ在肝癌诊断中的应用[J]. 临床和实验医学杂志, 2014, 13(7): 513-516. doi: 10.3969/j.issn.1671-4695.2014.07.001
[19]	李恒, 涂从银. 血清维生素K缺乏诱导蛋白Ⅱ检测对原发性肝癌的诊疗价值[J]. 肝胆胰外科杂志, 2019, 31(7): 412-416.
[20]	Zakhary N I, Khodeer S M, Shafik H E, et al. Impact of PIVKA-Ⅱ in diagnosis ofhepatocellular carcinoma[J]. J Adv Res, 2013, 4(6): 539-546. doi: 10.1016/j.jare.2012.10.004
[21]	邢昊, 韩骏. 应用血清PIVKA-Ⅱ诊断肝细胞癌研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 934-937. doi: 10.3969/j.issn.1672-5069.2019.06.040
[22]	安云飞, 蔡蓓, 苏真珍, 等. 血清AFP、AFP-L3和PIVKA-Ⅱ在诊断肝癌中的临床应用评估[J]. 中华临床实验室管理电子杂志, 2019, 7(2): 75-79. doi: 10.3877/cma.j.issn.2095-5820.2019.02.003
[23]	董静肖, 杨晓欢, 王琦, 等. 异常凝血酶原和甲胎蛋白对肝细胞癌诊断价值的比较研究[J]. 标记免疫分析与临床, 2019,26(10):1633-1637.
[24]	Ricco G, Cavallone D, Cosma C, et al. Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers[J]. Cancer Biomark, 2018,21(3):603-612.
[25]	Caviglia GP, Ribaldone DG, Abate ML, et al. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis[J]. Scand J Gastroenterol, 2018,53(6):734-740.

Relative Articles(20)

Relative Articles

[1]	Rui YIN, Guowei MA, Wenxi YUE, Haixia GU, Ying ZHOU, Jie CHEN. Efficacy of Nucleotide Analog Monotherapy and Combination Therapy with Interferon in Treating Chronic Hepatitis B. Journal of Kunming Medical University, 2024, 46(): 1-10.
[2]	Chunyan CHEN, Zimian FAN. Correlation Analysis of Peripheral Blood SAA/CRP and NLR Levels with HBV-DNA Lload and Degree of Disease in CHB Patients. Journal of Kunming Medical University, 2024, 45(5): 144-150. doi: 10.12259/j.issn.2095-610X.S20240522
[3]	Yixuan CHEN, Lin WANG, Xiuhong XIA, Zaikun PENG, Yi DING, Runjiao SHI, Xuefen LEI. Research Progress on the Mechanisms of Autophagy in Hepatocellular Carcinoma. Journal of Kunming Medical University, 2023, 44(4): 159-164. doi: 10.12259/j.issn.2095-610X.S20230416
[4]	Ming ZHANG, Chenglong YU, Jinpeng CAO. ZNF384 Regulates Metastasis of Hepatocellular Carcinoma via GCLM. Journal of Kunming Medical University, 2023, 44(11): 56-62. doi: 10.12259/j.issn.2095-610X.S20231108
[5]	Kang HUANG, Zhirong ZHAO, Haiwen LI, Ti WU, Ting JIA, Lu WANG, Nihong LU, Yongrui YANG. Efficacy and Safety of Sofosbuvir/Velpatasvir with or without Ribavirin in Cirrhotic Patients with Genotype 3 Chronic Hepatitis C Infection. Journal of Kunming Medical University, 2023, 44(11): 126-134. doi: 10.12259/j.issn.2095-610X.S20231119
[6]	Tianhong ZHANG, Hongju YANG. Research Progress of Exosomal miRNA in Hepatocellular Carcinoma. Journal of Kunming Medical University, 2022, 43(2): 150-153. doi: 10.12259/j.issn.2095-610X.S20220221
[7]	Haiyan FU, Junfang YAN, Hongjuan LI, Lin WANG, Jie ZHANG, Yujun ZHOU, Bin XU, Yu LUO. Effect of Time Interval on the Outcome with Transarterial Chemoembolization Followed Microwave Ablation with Hepatocellular Carcinoma. Journal of Kunming Medical University, 2022, 43(11): 63-70. doi: 10.12259/j.issn.2095-610X.S20221127
[8]	Yanwen XU, Xin WANG, Hua JIANG, Chenchen LIANG, Li LIU, Shenghao LI, Jianpeng GAO. Efficacy and Safety of Sofosbuvir-based Drugs for the Treatment of Patients with Chronic Hepatitis C Genotype 3： A Single Centre Real-world Retrospective Analysis. Journal of Kunming Medical University, 2022, 43(11): 124-129. doi: 10.12259/j.issn.2095-610X.S20221115
[9]	Zhi-rong ZHAO, Hai-wen LI, Xiao-fei LI, Ni-hong LU, Yong-rui YANG. Efficacy and Safety of Sofosbuvir/Vipatavir Combined with Ribavirin in Treatment of Genotype 3 Patients with Chronic Hepatitis C. Journal of Kunming Medical University, 2021, 42(3): 98-103. doi: 10.12259/j.issn.2095-610X.S20210325
[10]	Zhi-rong ZHAO, Hai-wen LI, Ni-hong LU, Ling SHEN, Xiao-fei LI, Yong-rui YANG. A Clinical Study on the Use of Propofol Tenofovir in the Treatment of Chronic Hepatitis B. Journal of Kunming Medical University, 2021, 42(1): 89-93. doi: 10.12259/j.issn.2095-610X.S20210141
[11]	Fan CAO, Yang-wen LIU, Lei WEI, Nan XIE, Yi-jian YANG, Cheng QIAN, Chun-mang LI, Bi-mang FU, Jiang-pin XU, Rong-ji YAN, Wang ZENG. Correlation between Hepatitis B Virus and Microvascular Invasion in Hepatocellular Carcinoma. Journal of Kunming Medical University, 2021, 42(3): 127-134. doi: 10.12259/j.issn.2095-610X.S20210331
[12]	Xie Wei , Zhao Chuan , Wang Rong , Wang Wen Ping , Tu Hong . . Journal of Kunming Medical University, 2020, 41(02): 82-86.
[13]	Tan Hua , Ren Hong , Zhao Ling , You Ding Yun , Yang Ya Chen . Prognostic Factors of Patients with Primary Hepatocellular Carcinoma Treated with TACE. Journal of Kunming Medical University, 2019, 40(03): 29-34.
[14]	Lei Xi Feng , Hou Feng Qiang , Liu Tao , Zhang Wei . . Journal of Kunming Medical University, 2018, 39(11): 11-15.
[15]	Lei Xi Feng , Hou Feng Qiang , Yang Shao Hua , Zhang Wei . . Journal of Kunming Medical University, 2018, 39(12): 49-53.
[16]	He Hai Yu . The Expression of GP73 in Serum and Tissues of Patients with Chronic Hepatitis B，Liver Cirrhosis and Primary Live r Cancer. Journal of Kunming Medical University,
[17]	Qiu Jian Wu . . Journal of Kunming Medical University,
[18]	Ning Lin . . Journal of Kunming Medical University,
[19]	Su Ying . . Journal of Kunming Medical University,
[20]	Yu Jie . . Journal of Kunming Medical University,